KKH Kaufmännische Krankenkasse
Germany · 300 open tenders · 487 documented awards
Current tenders
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the aforementioned active ingredients with the possibility of conclusion within the framework of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the named active ingredients with the possibility of concluding agreements within the scope of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the aforementioned active ingredients with the possibility of concluding agreements within the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the named active substances with the possibility of conclusion within the scope of the so-called Open-House procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a (8) SGB V for the named active substances with the possibility of conclusion within the framework of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive rebate agreements pursuant to § 130a para. 8 SGB V for the aforementioned active substances with the possibility of conclusion within the framework of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a paragraph 8 SGB V for the active substances mentioned with the possibility of conclusion within the scope of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a (8) SGB V for the active ingredients mentioned with the possibility of conclusion within the framework of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a (8) SGB V for the active ingredients mentioned with the possibility of concluding agreements within the framework of the so-called open house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the mentioned active ingredients with the possibility of conclusion within the scope of the so-called Open-House procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the stated active ingredients with the possibility of conclusion within the framework of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the aforementioned active ingredients with the option to conclude within the scope of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the named active ingredients with the possibility of conclusion within the framework of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the active substances mentioned, with the option to conclude agreements within the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the aforementioned active substances with the possibility of conclusion within the framework of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the stated active ingredients with conclusion possibility within the framework of the so-called Open-House procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the aforementioned active ingredients with the possibility of concluding agreements within the framework of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the named active ingredients with the option to conclude within the scope of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the named active substances with possibility of conclusion within the scope of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the aforementioned active substances with the possibility of conclusion as part of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a(8) SGB V for the named active substances with the possibility of conclusion within the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a (8) SGB V for the aforementioned active ingredients with the option to conclude agreements within the scope of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the active substances mentioned with the possibility of conclusion within the framework of the so-called Open-House procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the aforementioned active ingredients with the option to conclude within the framework of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a (8) SGB V for the active substances mentioned with the possibility of conclusion within the scope of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the aforementioned active substances with conclusion option within the scope of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the aforementioned active ingredients with the possibility of conclusion within the scope of the so-called open-house procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a paragraph 8 SGB V for the named active ingredients with the option to conclude within the framework of the so-called Open-House procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a para. 8 SGB V for the named active substances with the option to conclude within the framework of the so-called Open-House procedure.
Deadline 31 Dec ·
Conclusion of non-exclusive discount agreements pursuant to § 130a (8) SGB V for the named active ingredients with the option to conclude within the framework of the so-called Open House procedure.
Deadline 31 Dec ·
Purchasing rhythm
Awards per year — who knows the rhythm prepares before the notice appears.
201881
201947
202029
202130
202258
2023140
202420
20259
20263
Clement What the numbers say about this buyer
- 16% of this buyer's awards went to companies that had already won here before (38 awards since 2017, spread over 32 companies). That is well below the national norm (45%) — this buyer switches suppliers more often than others.n = 38 awards since 2017
- The median procedure drew 4 bids (38 procedures with a bid count); 16% ended with a single bidder. Country: median 3.1 bids.n = 38
- Not one of the 38 awards with a known winner country has gone to a foreign company so far. National average: 1%.n = 38
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Who has won here before
| Company | Awards | Period |
|---|---|---|
| betapharm Arzneimittel GmbH · Augsburg | 8 | 2013–2016 |
| mibe GmbH Arzneimittel · Sandersdorf-Brehna | 8 | 2013–2016 |
| neuraxpharm Arzneimittel GmbH · Langenfeld | 8 | 2013–2016 |
| Basics GmbH · Leverkusen | 8 | 2013–2016 |
| Aliud Pharma GmbH · Laichingen | 8 | 2013–2016 |
| Bluefish Pharma GmbH · Griesheim | 7 | 2013–2016 |
| 1 A Pharma GmbH · Oberhaching | 7 | 2013–2016 |
| TAD Pharma GmbH · Cuxhaven | 7 | 2013–2016 |
| SANIMED GmbH · Ibbenbüren | 7 | 2012–2018 |
| Hexal AG · Holzkirchen | 7 | 2013–2016 |
From 18.0M documented awards · regular winners know this buyer's requirements — that is your competition.